Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Oculis Holding AG - Ordinary shares (NQ: OCS )

11.38 -0.02 (-0.18%)
Streaming Delayed Price Updated: 2:48 PM EDT, Jul 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,449
Open 11.15
Bid (Size) 4.520 (2)
Ask (Size) 13.00 (4)
Prev. Close 11.40
Today's Range 11.15 - 11.40
52wk Range 9.050 - 14.50
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Alphabet To Rally Over 28%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
OCS Stock Earnings: Oculis Holding Misses EPS, Misses Revenue for Q1 2024
OCS stock results show that Oculis Holding missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
+2.99%
+2.99%
1 Month
-3.97%
-3.97%
3 Month
-4.81%
-4.81%
6 Month
+0.89%
+0.89%
1 Year
-8.00%
-8.00%

More News

Read More
FLJ Group, Bit Digital And Other Big Stocks Moving Higher In Friday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
Expert Ratings for Oculis Holding
Via Benzinga
What 4 Analyst Ratings Have To Say About Oculis Holding
Via Benzinga
Expert Ratings for Oculis Holding
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2023
Via Benzinga
Oculis Announces Partial Exercise of Underwriters’ Option to Purchase Additional Ordinary Shares
From Oculis SA
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 12, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 8, 2023
Via Benzinga
Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease
Via Newsfile
Oculis Announces Pricing of $40.25 Million Public Offering of Ordinary Shares
From Oculis SA
Via GlobeNewswire
Intel, Noah Holdings, Twilio And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Oculis Announces Launch of Proposed Public Offering of Ordinary Shares
From Oculis SA
Via GlobeNewswire
Oculis to Participate and Present at Upcoming EuDES Meeting
From Oculis SA
Via GlobeNewswire
Oculis Announces Positive Top Line Results from DIAMOND Stage 1 Phase 3 Trial in Diabetic Macular Edema with OCS-01 Eye Drops
From Oculis SA
Via GlobeNewswire
Oculis Co-founders Selected as Finalists in European Inventor Award 2023
From Oculis SA
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2023
Via Benzinga
Oculis Opens New Offices in the US and Expands its US Team by Appointing Dr. Fang Li as Senior Vice President, Regulatory Affairs
From Oculis SA
Via GlobeNewswire
Harley-Davidson, Sportsman's Warehouse And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Why GE HealthCare Technologies Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Oculis to Participate at Upcoming Investor Conferences
From Oculis SA
Via GlobeNewswire
Oculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline and Near-Term Clinical Milestones
From Oculis SA
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.